Abstract
The SCHEDULE trial investigated whether initiation of the proliferation signal inhibitor everolimus and early cyclosporine avoidance could improve renal function and reduce cardiac allograft vasculopathy in de-novo heart transplant recipients. After 12 months, we reported significantly higher measured glomerular filtration rates (mGFR) among patients treated with everolimus vs. conventional cyclosporine (79.8±17.7 vs. 61.5±19.6 mL/kg/1.73 m2; p<0.001), and significantly reduced incidence of cardiac allograft vasculopathy (CAV) (50.0% vs. 64.6%; p=0.003) and CAV progression (Δ maximal intimal thickness; 0.03±0.06 vs. 0.08±0.12 mm; p<0.01) assessed by IVUS. Both developments in mGFR and CAV remained significantly in favor of everolimus treatment also in our reports after 36 months. With a further extension of the treatment period to 6 years, results of renal function and CAV according to study arm will be presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
